Circle Pharma Raises $92.5 Million for Direct Cyclin D1 Inhibition

Company Circle Pharma Event Type Financing (Series E) Platform MXMO Macrocycle Platform — Oral Cyclin D1-Rb Protein-Protein Interaction Inhibitor Indication Estrogen-Receptor-Positive Breast Cancer Summary Circle Pharma closed an oversubscribed $92.5 million Series E led by The Column Group, with Nextech Invest, RA Capital Management, Euclidean…